美国据报要求临床测试新冠疫苗 Novavax 低收半成

The Wall Street Journal reported that after the U.S. Food and Drug Administration (FDA) requested Novavax (NVAX.US) to conduct another clinical trial for its COVID-19 vaccine, the full approval of the Novavax vaccine may be delayed, causing the company to close down more than 5% against the market trend.

Novavax stated that the U.S. Food and Drug Administration (FDA) is seeking more data as part of a "post-approval commitment," which typically involves studying the safety and efficacy of a product after it has been approved. The Novavax vaccine has been marketed under conditional approval